Reported about 1 year ago
Antro Biotech announced on July 2, 2024, that their Enterovirus 71 vaccine (EnVAX-A71) passed the Phase III clinical trial with an efficacy rate of 99.12%, the highest among all Enterovirus 71 vaccines in the global market. Antro plans to apply for listing on the Taiwan Stock Exchange's innovation board in mid-July. The company has also signed a sales contract with VABIOTECH, Vietnam's largest state-owned vaccine company, aiming to enter the newborn market in Southeast Asia and potentially expand to mainland China. Antro's vaccine trial involved multiple countries and centers, with impressive results.
Source: YAHOO